Gabriel Pardo

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 173 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +5

Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome

Darin T. Okuda, Orhun H. Kantarci, Christine Lebrun‐Frénay et al. · Annals of Neurology · 2022 · 113 citations

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model

Neelakshi R. Jog, Micah T. McClain, Latisha Heinlen et al. · Journal of Autoimmunity · 2019 · 86 citations · Full text

Autoimmune Disease, Neurological Disorder, Medicine +11